CMS reverts to Medicare Part D reimbursements of ASP plus 6%. HRSA warned AbbVie and Amgen, and referred Merck for possible fines, over their contract pharmacy policies.

By now, you’re painfully aware there’s a fiercely contested midterm election taking place Nov. 8, with control of the U.S. House and Senate in the balance. And while 340B may not get much airtime on the campaign trail, the stakes are high for the discount drug program.

When you combine critical access hospitals (CAHs) and the home office for the National Rural Health Association in Kansas City, you have a great gathering of leadership with a bit of BBQ!

An entire season has now come and gone since the U.S. Supreme Court ruled that the federal government unlawfully shorted 340B hospitals on Medicare Part B payments.

As the days grow shorter and kids head back to school, we can celebrate a little good news here in the late summer.

As we’ve noted before, 2022 is the year when 340B turns 30! Its birthday is Nov. 4 to be exact, however, when it’s a milestone year, you celebrate all year long.

T.J. Regional Health, based in Glasgow, Ky., had been running a 340B program for well over a decade before it enlisted the help of Sentry Data Systems, now The Craneware Group.

Welcome to the dog days of summer. Like much of the country, the temperature is slowly being turned up underneath the 340B pot and it’s downright hot in the kitchen.

Efforts by drug manufacturers and their allies to undermine 340B have created a lot of misunderstanding about the discount drug program.